Casey F Pulliam
Overview
Explore the profile of Casey F Pulliam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singhania M, Zaher A, Pulliam C, Bayanbold K, Searby C, Schoenfeld J, et al.
Int J Mol Sci
. 2024 Feb;
25(4.
PMID: 38397073
Cancer cells frequently present elevated intracellular iron levels, which are thought to facilitate an enhanced proliferative capacity. Targeting iron metabolism within cancer cells presents an avenue to enhance therapeutic responses,...
2.
Mapuskar K, Pulliam C, Tomanek-Chalkley A, Rastogi P, Wen H, Dayal S, et al.
Redox Biol
. 2024 Jan;
70:103022.
PMID: 38215546
Purpose: Cisplatin contributes to acute kidney injury (AKI) and chronic kidney disease (CKD) that occurs with greater frequency and severity in older patients. Age-associated cisplatin sensitivity in human fibroblasts involves...
3.
Bayanbold K, Singhania M, Fath M, Searby C, Stolwijk J, Henrich J, et al.
Antioxidants (Basel)
. 2023 Nov;
12(11).
PMID: 38001858
The intracellular redox-active labile iron pool (LIP) is weakly chelated and available for integration into the iron metalloproteins that are involved in diverse cellular processes, including cancer cell-specific metabolic oxidative...
4.
Mapuskar K, Pulliam C, Zepeda-Orozco D, Griffin B, Furqan M, Spitz D, et al.
Antioxidants (Basel)
. 2023 Sep;
12(9).
PMID: 37760031
Cisplatin, a potent chemotherapeutic agent, is marred by severe nephrotoxicity that is governed by mechanisms involving oxidative stress, inflammation, and apoptosis pathways. The transcription factor Nrf2, pivotal in cellular defense...
5.
Bullert A, Li X, Zhang C, Lee K, Pulliam C, Cagle B, et al.
bioRxiv
. 2023 Aug;
PMID: 37609242
Highlights: PCB 52 was present in adipose, brain, liver, and serum 3 weeks after PCB exposureLiver and serum contained hydroxylated, sulfated, and methylated PCB 52 metabolitesMetabolomics analysis revealed minor changes...
6.
Bullert A, Li X, Chunyun Z, Lee K, Pulliam C, Cagle B, et al.
Environ Toxicol Pharmacol
. 2023 Aug;
102:104245.
PMID: 37572994
The disposition and toxicity of lower chlorinated PCBs (LC-PCBs) with less than five chlorine substituents have received little attention. This study characterizes the distribution and metabolomic effects of PCB 52,...
7.
Allen B, Alaghband Y, Kramar E, Ru N, Petit B, Grilj V, et al.
Neuro Oncol
. 2022 Nov;
25(5):927-939.
PMID: 36334265
Background: Ultrahigh dose-rate radiotherapy (FLASH-RT) affords improvements in the therapeutic index by minimizing normal tissue toxicities without compromising antitumor efficacy compared to conventional dose-rate radiotherapy (CONV-RT). To investigate the translational...
8.
OMalley Y, Coleman M, Sun X, Lei J, Yao J, Pulliam C, et al.
Adv Redox Res
. 2022 Jul;
5.
PMID: 35903252
Cystic fibrosis-related diabetes (CFRD) is one the most common comorbidities in cystic fibrosis (CF). Pancreatic oxidative stress has been postulated in the pathogenesis of CFRD, but no studies have been...
9.
Furqan M, Abu-Hejleh T, Stephens L, Hartwig S, Mott S, Pulliam C, et al.
Redox Biol
. 2022 May;
53:102318.
PMID: 35525024
Purpose: Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that...
10.
Sishc B, Ding L, Nam T, Heer C, Rodman S, Schoenfeld J, et al.
Sci Transl Med
. 2021 May;
13(593).
PMID: 33980575
Avasopasem manganese (AVA or GC4419), a selective superoxide dismutase mimetic, is in a phase 3 clinical trial (NCT03689712) as a mitigator of radiation-induced mucositis in head and neck cancer based...